Company Bellicum Pharmaceuticals, Inc. OTC Markets
Equities
BLCM
US0794814048
Biotechnology & Medical Research
Business Summary
Number of employees: 13
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cellular Immunotherapies
100.0
%
| 6 | 100.0 % | 2 | 100.0 % | -75.81% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 2 | 100.0 % | -75.81% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,901,026 | 11,716,439 ( 98.45 %) | 67,746 ( 0.5692 %) | 98.45 % |
Stock B | 0 | 452,000 | 0 | 0 |
Company contact information
Bellicum Pharmaceuticals, Inc.
3730 Kirby Drive Suite 1200
77098, Houston
+281 454 3424
http://www.bellicum.comSector
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |